On Wednesday, Urban-gro, Inc. (NASDAQ: UGRO) reported first-quarter results and reaffirms full-year 2023 guidance.
CEO Bradley Nattrass highlighted the company's focus on creating a durable and diversified organization.
- Over 8,000 patients 12 years of age and older with severe sickle cell disease or transfusion-dependent beta thalassemia may be eligible for treatment -
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced